Establishment of a Prognostic Model Using Immune-Related Genes in Patients With Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC) is one of the most prevalent neoplasms worldwide, particularly in China. Immune-related genes (IRGs) and immune infiltrating lymphocytes play specific roles in tumor growth. Considering how important immunotherapy has become for HCC treatment in the past decade, our objective was to establish a prognostic model by screening survival-related IRGs in patients with HCC.

Screening and validation of tumor-associated genes in human hepatocellular carcinoma tissues.

Background/aims: We used gene expression profile detected by Gene chip to investigate the pathogenesis of hepatocellular carcinoma (HCC) and screen for early diagnostic markers.

Methodology: Differentially expressed genes between HCC and normal liver tissues were screened by using Gene Expression Profile Chip with 14,500 distinct genes. Some selected differentially expressed genes were validated using reverse transcription polymerase chain reaction (RT-PCR) for the gene level and using immunohistochemistry for the protein level.

[Expression and its clinicopathological features of tumor rejective antigen 1 in human tissues of hepatocellular carcinoma and liver cirrhosis].

Objective: To investigate the expression of tumor rejective antigen 1 in hepatocellular carcinoma (HCC) and liver cirrhosis(LC) tissues, and the relationship between clinicopathological feature and HCC.

Methods: The expressions of TRA1 mRNA and its protein were detected by reverse transcription polymerase chain reaction (RT-PCR) and Western blot respectively. Immunohistochemical staining was used to further examine the expression of TRA1 protein in LC, HCC and control tissues.